Allen Cato

Chief Executive & Medical Officer at Cancer Advances, Inc.

Allen Cato

Allen Cato

Chief Executive & Medical Officer at Cancer Advances, Inc.

Overview
Career Highlights

Advanced Pain Remedies, Inc.
Cancer Advances, Inc.
Cato BioVentures

RelSci Relationships

177

Number of Boards

5

Contact Data
Trying to get in touch with Allen Cato? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Allen Cato likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at CATO Research Ltd.

Relationship likelihood: Strong

Chief Financial Officer at CATO Research Ltd.

Relationship likelihood: Strong

Chief Operating Officer at CATO Research Ltd.

Relationship likelihood: Strong

Vice President-Quality Assurance at CATO Research Ltd.

Relationship likelihood: Strong

Chief Executive Officer at VistaGen Therapeutics, Inc.

Relationship likelihood: Strong

Director of Clinical Pharmacology at Thomas Jefferson University Hospital

Relationship likelihood: Strong

Managing Director, CATO Research Boston at CATO Research Ltd.

Relationship likelihood: Strong

Executive Chairman at CATO Research Ltd.

Relationship likelihood: Strong

Chief Legal Officer at Cato BioVentures

Relationship likelihood: Strong

Managing Director of CATO Research San Diego at CATO Research Ltd.

Relationship likelihood: Strong

Paths to Allen Cato
Potential Connections via
Relationship Science
You
Allen Cato
Chief Executive & Medical Officer at Cancer Advances, Inc.
Career History
Co-Founder
1988 - Current

Cato BioVentures focuses on early-stage investment opportunities in private companies and PIPE opportunities in undervalued public companies in the life sciences sector. They target innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development. Cato BioVentures seeks companies with novel therapeutics for central and peripheral nervous system disorders, cardiovascular disease, metabolic disease and cancer, with special emphasis on next generation embryonic stem cell-based technologies and skin penetration enhancement delivery systems. Cato BioVentures also seeks product development opportunities in public companies that have gone off track or fallen out of favor with the investment community. The firm's strategic services often serve as a bridge during the period between a company's formation or initial angel financing and its first institutional financing.Cato BioVentures often co-invests with other institutional investors and they generally do not require a board seat as a condition of their investment. In a board-like manner, the firm's principals regularly provide essential market, regulatory and drug development insights, as well as financial, operational and strategic advice.Cato seeks to invest in companies with a realistic business model built on reasonable assumptions, innovative drug candidates or technologies supported by a strong intellectual property position and a solid pathway to commercial protection. They prefer companies targeting a large market potential (at least $100 million in annual sales) within a reasonable amount of time (up to seven years) based upon a realistic analysis of the market from the bottom up.

Chief Executive & Medical Officer
Current

Cancer Advances, Inc. develops treatment of gastrointestinal cancers. It also develops variety of immunomodulators which includes adaptive T-cells, therapeutic vaccines, and monoclonal antibodies for the treatment of gastric and pancreatic cancer. The company was founded in 2008 and is headquartered in Durham, NC.

Co-Founder
1998 - ?

Cato Research LLC operates as an international regulatory and clinical contract research organization. It offers clinical strategy, clinical trial services, data management and biostatistics, medical and pharmacovigilance, medical writing, pharmacokinetics, preclinical/nonclinical services, project management, quality assurance, and regulatory affairs. The company was founded by Allen Cato and Lynda Sutton in 1988 and is headquartered in Durham, NC.

Boards & Committees
Director
1998 - Current

Cato Research LLC operates as an international regulatory and clinical contract research organization. It offers clinical strategy, clinical trial services, data management and biostatistics, medical and pharmacovigilance, medical writing, pharmacokinetics, preclinical/nonclinical services, project management, quality assurance, and regulatory affairs. The company was founded by Allen Cato and Lynda Sutton in 1988 and is headquartered in Durham, NC.

Chairman
Current

Hemodynamic Therapeutics, Inc. develops a novel small molecule combination therapy for obesity-related hypertension. The firm is developing its novel small molecule combination therapy (HTI-101) for obesity-related hypertension, one of the world's fastest growing cardiovascular disease markets. It has recently completed an initial Phase 2 clinical trial of HTI-101 in obese individuals with mild to moderate treatment-resistant hypertension. The company was founded in 2004 and is headquartered in Raleigh, NC.

Director
Prior

Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded on September 14, 2007 and is headquartered in Iselin, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Allen Cato. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Allen Cato's profile does not indicate a business or promotional relationship of any kind between RelSci and Allen Cato.